ALLMedicine™ Astrocytoma Center
Research & Reviews 1,536 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095826
Pathology Oncology Research : POR; Chang SJ, Chao CT et. al.
May 17th, 2022 - Background: CXCL13 may act as a mediator of tumor-associated macrophage immunity during malignant progression. Objective: The present study clarifies the clinicopathological significances of CXCL13 and its corresponding trend with M2 macrophage in...
https://clinicaltrials.gov/ct2/show/NCT05375318
May 16th, 2022 - High-grade glioma (HGG) are the most aggressive malignant primary brain tumor in adults with a median survival rate of 12-15 months. It still carries a poor prognosis despite aggressive treatment, which includes tumor resection followed by chemo-r...
https://clinicaltrials.gov/ct2/show/NCT04782609
May 9th, 2022 - This is a 2-part multicenter Phase 1b study designed to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation des...
https://doi.org/10.1158/1078-0432.CCR-21-2830
Clinical Cancer Research : an Official Journal of the Ame... Kumar A, Mohamed E et. al.
May 6th, 2022 - The immunosuppressive tumor microenvironment present in the majority of diffuse glioma limits therapeutic response to immunotherapy. As the determinants of the glioma-associated immune response are relatively poorly understood, the study of glioma...
https://doi.org/10.1007/s00381-022-05528-1 10.3345/kjp.2015.58.1.28 10.1016/s0022-3476(76)80260-0 10.1542/peds.2004-2237 10.1542/peds.2012-3196 10.3340/jkns.2018.0056 10.1007/s11060-021-03709-7 10.1007/s00432-018-2743-0 10.3171/2018.9.PEDS18181 10.1016/S1470-2045(05)70245-X 10.4103/0028-3886.314587
Child's Nervous System : ChNS : Official Journal of the I... Ju Y, Liu P et. al.
May 5th, 2022 - Diencephalic syndrome (DS) is a rare syndrome with failure to thrive (FTT) as the primary manifestation, which is often associated with astrocytoma or glioma and rarely caused by germinoma. To our knowledge, there are no reports of female patients...
Guidelines 3 results
https://doi.org/10.1200/JCO.21.02036
Journal of Clinical Oncology : Official Journal of the Am... Mohile NA, Messersmith H et. al.
Dec 14th, 2021 - To provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature. Fifty-nine rand...
https://doi.org/10.1007/s11060-015-1931-x
Journal of Neuro-oncology; Ziu M, Kalkanis SN et. al.
Nov 5th, 2015 - Adult patients (older than 18 years of age) with newly diagnosed World Health Organization (WHO) Grade II gliomas (Oligodendroglioma, astrocytoma, mixed oligoastrocytoma). Is there a role for chemotherapy as adjuvant therapy of choice in treatment...
https://doi.org/10.1007/s11060-015-1867-1
Journal of Neuro-oncology; Aghi MK, Nahed BV et. al.
Nov 5th, 2015 - Should patients with imaging suggestive of low grade glioma (LGG) undergo observation versus treatment involving a surgical procedure? These recommendations apply to adults with imaging suggestive of a WHO grade 2 glioma (oligodendroglioma, astroc...
Drugs 31 results see all →
Clinicaltrials.gov 47 results
https://clinicaltrials.gov/ct2/show/NCT05375318
May 16th, 2022 - High-grade glioma (HGG) are the most aggressive malignant primary brain tumor in adults with a median survival rate of 12-15 months. It still carries a poor prognosis despite aggressive treatment, which includes tumor resection followed by chemo-r...
https://clinicaltrials.gov/ct2/show/NCT04782609
May 9th, 2022 - This is a 2-part multicenter Phase 1b study designed to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation des...
https://clinicaltrials.gov/ct2/show/NCT04430842
Apr 19th, 2022 - This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expre...
https://clinicaltrials.gov/ct2/show/NCT03561207
Apr 8th, 2022 - This protocol defines a prospective, open-label, multi-institutional, non-interventional study for the purpose of examining the Assay's clinical use and potential to impact patient outcomes. This Study will establish a registry of clinical paramet...
https://clinicaltrials.gov/ct2/show/NCT03763422
Feb 1st, 2022 - The 1635-EORTC-BTG study - Wait or Treat - concerns patients that represent a clinically favorable group of patients with IDHmutated astrocytoma (oligo-symptomatic), without a need for immediate post-operative treatment. It will establish whether ...
News 68 results
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma
Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...
https://www.onclive.com/view/net-guides-childhood-tumors
Mar 15th, 2022 - //THE ONLINE ONCOLOGIST™ American Society of Pediatric Hematology/Oncology The American Society of Pediatric Hematology/Oncology (ASPHO) is a multidisciplinary organization that works to promote the care of children and adolescents with blo...
https://www.medscape.com/viewarticle/968594
Feb 15th, 2022 - New research shows that men in their 20s and 30s have worse survival from many different types of brain tumors than women of the same age. And, researchers say, it’s not exactly clear why. Differences in treatment may mediate some of the associati...
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer
Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...
https://www.onclive.com/view/selumetinib-response-not-driven-by-mapk-expression-in-pediatric-and-aya-refractory-solid-tumors
Jun 10th, 2021 - Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway, according to cohort findings from the phase 2, single-arm National Cancer I...